

Ira Pastan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6808644/publications.pdf>

Version: 2024-02-01

405
papers

28,439
citations

5126

86
h-index

8627

151
g-index

406
all docs

406
docs citations

406
times ranked

17887
citing authors

#	ARTICLE	IF	CITATIONS
1	GPC1-Targeted Immunotoxins Inhibit Pancreatic Tumor Growth in Mice via Depletion of Short-lived GPC1 and Downregulation of Wnt Signaling. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 960-973.	1.9	4
2	Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 1195-1206.	1.9	18
3	Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by shed mesothelin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2202439119.	3.3	8
4	Intraductal administration of transferrin receptor-targeted immunotoxin clears ductal carcinoma in situ in mouse models of breast cancer—a preclinical study. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	8
5	Stabilization of hypoxia-inducible factor ameliorates glomerular injury sensitization after tubulointerstitial injury. <i>Kidney International</i> , 2021, 99, 620-631.	2.6	13
6	Phase I study of mesothelin-targeted immunotoxin LMB-100 in combination with tofacitinib in persons with pancreatobiliary cancer or other mesothelin expressing solid tumors.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS452-TPS452.	0.8	3
7	Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial. <i>Journal of Hematology and Oncology</i> , 2021, 14, 35.	6.9	51
8	Indirect podocyte injury manifested in a partial podocytectomy mouse model. <i>American Journal of Physiology - Renal Physiology</i> , 2021, 320, F922-F933.	1.3	9
9	Phase 1 trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox combined with rituximab for relapsed/refractory hairy cell leukemia.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7036-7036.	0.8	0
10	Phase I study of mesothelin-targeted immunotoxin LMB-100 in combination with tofacitinib in patients with advanced pancreatobiliary cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3051-3051.	0.8	3
11	Moxetumomab pasudotox as re-treatment for heavily-pretreated relapsed hairy cell leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 2812-2814.	0.6	8
12	Immunotherapy-based targeting of MSLN ⁺ activated portal fibroblasts is a strategy for treatment of cholestatic liver fibrosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	11
13	Immunotoxins: From Design to Clinical Application. <i>Biomolecules</i> , 2021, 11, 1696.	1.8	6
14	Engineered Anti-GPC3 Immunotoxin, HN3-ABD-20, Produces Regression in Mouse Liver Cancer Xenografts Through Prolonged Serum Retention. <i>Hepatology</i> , 2020, 71, 1696-1711.	3.6	42
15	Site-Specific PEGylation of Anti-Mesothelin Recombinant Immunotoxins Increases Half-life and Antitumor Activity. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 812-821.	1.9	14
16	Contextualizing the Use of Moxetumomab Pasudotox in the Treatment of Relapsed or Refractory Hairy Cell Leukemia. <i>Oncologist</i> , 2020, 25, e170-e177.	1.9	15
17	Development of Recombinant Immunotoxins for Hairy Cell Leukemia. <i>Biomolecules</i> , 2020, 10, 1140.	1.8	18
18	Mechanisms of Resistance to Immunotoxins Containing Pseudomonas Exotoxin A in Cancer Therapy. <i>Biomolecules</i> , 2020, 10, 979.	1.8	20

#	ARTICLE	IF	CITATIONS
19	Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin. <i>Cancer</i> , 2020, 126, 4936-4947.	2.0	31
20	Multiple proteases are involved in mesothelin shedding by cancer cells. <i>Communications Biology</i> , 2020, 3, 728.	2.0	17
21	Immunotoxin SS1P is rapidly removed by proximal tubule cells of kidney, whose damage contributes to albumin loss in urine. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 6086-6091.	3.3	13
22	Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti-PD-1 antibody in patients with mesothelioma and mouse tumor models. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	28
23	Immunogenicity of Immunotoxins Containing Pseudomonas Exotoxin A: Causes, Consequences, and Mitigation. <i>Frontiers in Immunology</i> , 2020, 11, 1261.	2.2	55
24	Population pharmacokinetics, efficacy, and safety of moxetumomab pasudotox in patients with relapsed or refractory hairy cell leukaemia. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1367-1376.	1.1	9
25	Results from an international phase 2 study of the anti-CD22 immunotoxin moxetumomab pasudotox in relapsed or refractory childhood lineage acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28112.	0.8	16
26	Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 828-836.	3.2	35
27	Diffuse mesothelin expression leads to worse prognosis through enhanced cellular proliferation in colorectal cancer. <i>Oncology Letters</i> , 2020, 19, 1741-1750.	0.8	21
28	Podocyte Injury Augments Intrarenal Angiotensin II Generation and Sodium Retention in a Megalin-Dependent Manner. <i>Hypertension</i> , 2019, 74, 509-517.	1.3	24
29	Anti-Mesothelin Recombinant Immunotoxin Therapy for Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2019, 18, 192-199.e1.	1.0	7
30	Pseudomonas Exotoxin Immunotoxins and Anti-Tumor Immunity: From Observations at the Patient's Bedside to Evaluation in Preclinical Models. <i>Toxins</i> , 2019, 11, 20.	1.5	37
31	Possible role of complement factor H in podocytes in clearing glomerular subendothelial immune complex deposits. <i>Scientific Reports</i> , 2019, 9, 7857.	1.6	21
32	Lipoprotein modulation of proteinuric renal injury. <i>Laboratory Investigation</i> , 2019, 99, 1107-1116.	1.7	9
33	Anti-BCMA immunotoxins produce durable complete remissions in two mouse myeloma models. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 4592-4598.	3.3	14
34	Depletion of regulatory T cells in tumors with an anti-CD25 immunotoxin induces CD8 T cell-mediated systemic antitumor immunity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 4575-4582.	3.3	70
35	Generation of a Transgenic BALB/c Mouse Line With Selective Expression of Human Mesothelin in Thyroid Gland: Application in Mesothelin-targeted Immunotherapy. <i>Journal of Immunotherapy</i> , 2019, 42, 119-125.	1.2	4
36	Interplay between reversible phosphorylation and irreversible ADP-ribosylation of eukaryotic translation elongation factor 2. <i>Biological Chemistry</i> , 2019, 400, 501-512.	1.2	3

#	ARTICLE	IF	CITATIONS
37	Global polysome analysis of normal and injured podocytes. American Journal of Physiology - Renal Physiology, 2019, 316, F241-F252.	1.3	16
38	Diphthamide affects selenoprotein expression: Diphthamide deficiency reduces selenocysteine incorporation, decreases selenite sensitivity and pre-disposes to oxidative stress. Redox Biology, 2019, 20, 146-156.	3.9	17
39	Moxetumomab Pasudotox-Tdfk in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 Trial. Blood, 2019, 134, 2808-2808.	0.6	8
40	A phase I study of mesothelin-targeted immunotoxin LMB-100 in combination with nab-paclitaxel for patients with previously treated advanced pancreatic cancer.. Journal of Clinical Oncology, 2019, 37, 307-307.	0.8	3
41	Pooled safety summary for patients treated with the CD22-directed cytotoxin moxetumomab pasudotox-tdfk.. Journal of Clinical Oncology, 2019, 37, 7014-7014.	0.8	0
42	Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up. Blood, 2018, 131, 2331-2334.	0.6	64
43	Low-Dose Methotrexate Prevents Primary and Secondary Humoral Immune Responses and Induces Immune Tolerance to a Recombinant Immunotoxin. Journal of Immunology, 2018, 200, 2038-2045.	0.4	9
44	5-Azacytidine prevents relapse and produces long-term complete remissions in leukemia xenografts treated with Moxetumomab pasudotox. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E1867-E1875.	3.3	12
45	Tolerogenic nanoparticles restore the antitumor activity of recombinant immunotoxins by mitigating immunogenicity. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E733-E742.	3.3	45
46	Improving the <i>In Vivo</i> Efficacy of an Anti-Tac (CD25) Immunotoxin by <i>Pseudomonas</i> Exotoxin A Domain II Engineering. Molecular Cancer Therapeutics, 2018, 17, 1486-1493.	1.9	14
47	Recombinant immunotoxins with albumin-binding domains have long half-lives and high antitumor activity. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E3501-E3508.	3.3	44
48	Cancer vaccine strategies: translation from mice to human clinical trials. Cancer Immunology, Immunotherapy, 2018, 67, 1863-1869.	2.0	38
49	Interactions Between Pseudomonas Immunotoxins and the Plasma Membrane: Implications for CAT-8015 Immunotoxin Therapy. Frontiers in Oncology, 2018, 8, 553.	1.3	5
50	SS1P Immunotoxin Induces Markers of Immunogenic Cell Death and Enhances the Effect of the CTLA-4 Blockade in AE17M Mouse Mesothelioma Tumors. Toxins, 2018, 10, 470.	1.5	23
51	Anti-drug antibodies to LMB-100 are enhanced by mAbs targeting OX40 and CTLA4 but not by mAbs targeting PD1 or PDL-1. Cellular Immunology, 2018, 334, 38-41.	1.4	10
52	Elevated Serum Megakaryocyte Potentiating Factor as a Predictor of Poor Survival in Patients with Mesothelioma and Primary Lung Cancer. journal of applied laboratory medicine, The, 2018, 3, 166-177.	0.6	6
53	Preclinical development of anti-BCMA immunotoxins targeting multiple myeloma. Antibody Therapeutics, 2018, 1, 19-25.	1.2	7
54	Domain II of Pseudomonas Exotoxin Is Critical for Efficacy of Bolus Doses in a Xenograft Model of Acute Lymphoblastic Leukemia. Toxins, 2018, 10, 210.	1.5	8

#	ARTICLE	IF	CITATIONS
55	Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. <i>Leukemia</i> , 2018, 32, 1768-1777.	3.3	184
56	Strategies to Reduce the Immunogenicity of Recombinant Immunotoxins. <i>American Journal of Pathology</i> , 2018, 188, 1736-1743.	1.9	52
57	Elimination of murine and human T-cell epitopes in recombinant immunotoxin eliminates neutralizing and anti-drug antibodies in vivo. <i>Cellular and Molecular Immunology</i> , 2017, 14, 432-442.	4.8	33
58	Rational design of low immunogenic anti CD25 recombinant immunotoxin for T cell malignancies by elimination of T cell epitopes in PE38. <i>Cellular Immunology</i> , 2017, 313, 59-66.	1.4	21
59	Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia. <i>Blood</i> , 2017, 130, 1620-1627.	0.6	57
60	Tubulointerstitial fibrosis can sensitize the kidney to subsequent glomerular injury. <i>Kidney International</i> , 2017, 92, 1395-1403.	2.6	36
61	Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anticancer Immunity. <i>Cancer Immunology Research</i> , 2017, 5, 685-694.	1.6	37
62	5'UTR point substitutions and N-terminal truncating mutations of ANKRD26 in acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , 2017, 10, 18.	6.9	33
63	Role of HLA-DP in the Presentation of Epitopes from the Truncated Bacterial PE38 Immunotoxin. <i>AAPS Journal</i> , 2017, 19, 117-129.	2.2	4
64	Efficacy of Anti-mesothelin Immunotoxin RG7787 plus Nab-Paclitaxel against Mesothelioma Patient-Derived Xenografts and Mesothelin as a Biomarker of Tumor Response. <i>Clinical Cancer Research</i> , 2017, 23, 1564-1574.	3.2	32
65	Construction of an immunotoxin, HN3-mPE24, targeting glypican-3 for liver cancer therapy. <i>Oncotarget</i> , 2017, 8, 32450-32460.	0.8	38
66	A combinatorial immunotherapy for malignant brain tumors: D2C7 immunotoxin and immune checkpoint inhibitors. <i>Journal of Clinical Oncology</i> , 2017, 35, 102-102.	0.8	1
67	Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma. <i>Oncotarget</i> , 2017, 8, 26744-26754.	0.8	38
68	Paclitaxel synergizes with exposure time adjusted CD22-targeting immunotoxins against B-cell malignancies. <i>Oncotarget</i> , 2017, 8, 30644-30655.	0.8	11
69	Panbinostat decreases cFLIP and enhances killing of cancer cells by immunotoxin LMB-100 by stimulating the extrinsic apoptotic pathway. <i>Oncotarget</i> , 2017, 8, 87307-87316.	0.8	14
70	Immunotoxin and bcl-2 inhibitor combination therapy targeting chondroitin sulfate proteoglycan 4. <i>Journal of Clinical Oncology</i> , 2017, 35, 74-74.	0.8	0
71	Protection of the Furin Cleavage Site in Low-Toxicity Immunotoxins Based on Pseudomonas Exotoxin A. <i>Toxins</i> , 2016, 8, 217.	1.5	24
72	Anti-TGF- β 2 Antibody, 1D11, Ameliorates Glomerular Fibrosis in Mouse Models after the Onset of Proteinuria. <i>PLoS ONE</i> , 2016, 11, e0155534.	1.1	23

#	ARTICLE	IF	CITATIONS
73	Immunogenicity of therapeutic recombinant immunotoxins. <i>Immunological Reviews</i> , 2016, 270, 152-164.	2.8	85
74	TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancer. <i>Oncolmmunology</i> , 2016, 5, e1197459.	2.1	24
75	Ranking Differential Drug Activities from Dose-Response Synthetic Lethality Screens. <i>Journal of Biomolecular Screening</i> , 2016, 21, 942-955.	2.6	4
76	Wide Variability in the Time Required for Immunotoxins to Kill B Lineage Acute Lymphoblastic Leukemia Cells: Implications for Trial Design. <i>Clinical Cancer Research</i> , 2016, 22, 4913-4922.	3.2	8
77	Actinomycin D enhances killing of cancer cells by immunotoxin RG7787 through activation of the extrinsic pathway of apoptosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 10666-10671.	3.3	54
78	Expression of mesothelin in thymic carcinoma and its potential therapeutic significance. <i>Lung Cancer</i> , 2016, 101, 104-110.	0.9	18
79	Mesothelin Immunotherapy for Cancer: Ready for Prime Time?. <i>Journal of Clinical Oncology</i> , 2016, 34, 4171-4179.	0.8	244
80	3D Culture Supports Long-Term Expansion of Mouse and Human Nephrogenic Progenitors. <i>Cell Stem Cell</i> , 2016, 19, 516-529.	5.2	153
81	Characterization of a re-engineered, mesothelin-targeted <i>Pseudomonas</i> exotoxin fusion protein for lung cancer therapy. <i>Molecular Oncology</i> , 2016, 10, 1317-1329.	2.1	45
82	Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin-Targeting Recombinant Immunotoxins. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1648-1655.	1.9	22
83	Protein Kinase Inhibitor H89 Enhances the Activity of <i>Pseudomonas</i> Exotoxin A-Based Immunotoxins. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1053-1062.	1.9	9
84	Anticancer Effects of Mesothelin-Targeted Immunotoxin Therapy Are Regulated by Tyrosine Kinase DDR1. <i>Cancer Research</i> , 2016, 76, 1560-1568.	0.4	15
85	Complete Remissions of Adult T-cell Leukemia with Anti-CD25 Recombinant Immunotoxin LMB-2 and Chemotherapy to Block Immunogenicity. <i>Clinical Cancer Research</i> , 2016, 22, 310-318.	3.2	48
86	New Life for Immunotoxin Cancer Therapy. <i>Clinical Cancer Research</i> , 2016, 22, 1055-1058.	3.2	38
87	Chemical Screens Identify Drugs that Enhance or Mitigate Cellular Responses to Antibody-Toxin Fusion Proteins. <i>PLoS ONE</i> , 2016, 11, e0161415.	1.1	8
88	EGFR/EGFRVIII-targeted immunotoxin therapy for the treatment of glioblastomas via convection-enhanced delivery. <i>Receptors & Clinical Investigation</i> , 2016, 3, .	0.9	11
89	Dual B- and T-cell de-immunization of recombinant immunotoxin targeting mesothelin with high cytotoxic activity. <i>Oncotarget</i> , 2016, 7, 29916-29926.	0.8	41
90	Quantification of recombinant immunotoxin delivery to solid tumors allows for direct comparison of in vivo and in vitro results. <i>Scientific Reports</i> , 2015, 5, 10832.	1.6	22

#	ARTICLE	IF	CITATIONS
91	Designing the Furin-Cleavable Linker in Recombinant Immunotoxins Based on <i>Pseudomonas</i> Exotoxin A. <i>Bioconjugate Chemistry</i> , 2015, 26, 1120-1128.	1.8	25
92	Immunoconjugates in the management of hairy cell leukemia. <i>Best Practice and Research in Clinical Haematology</i> , 2015, 28, 236-245.	0.7	24
93	Tumor and organ uptake of ⁶⁴ Cu-labeled MORAb-009 (amatuximab), an anti-mesothelin antibody, by PET imaging and biodistribution studies. <i>Nuclear Medicine and Biology</i> , 2015, 42, 880-886.	0.3	11
94	Podocyte injury-driven intracapillary plasminogen activator inhibitor type 1 accelerates podocyte loss via uPAR-mediated α 1-integrin endocytosis. <i>American Journal of Physiology - Renal Physiology</i> , 2015, 308, F614-F626.	1.3	45
95	Bortezomib Reduces Pre-Existing Antibodies to Recombinant Immunotoxins in Mice. <i>Journal of Immunology</i> , 2015, 194, 1695-1701.	0.4	11
96	Advances in Anticancer Immunotoxin Therapy. <i>Oncologist</i> , 2015, 20, 176-185.	1.9	161
97	Whole-genome RNAi screen highlights components of the endoplasmic reticulum/Golgi as a source of resistance to immunotoxin-mediated cytotoxicity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E1135-42.	3.3	22
98	Unilateral ureteral obstruction attenuates intrarenal angiotensin II generation induced by podocyte injury. <i>American Journal of Physiology - Renal Physiology</i> , 2015, 308, F932-F937.	1.3	2
99	New High Affinity Monoclonal Antibodies Recognize Non-Overlapping Epitopes On Mesothelin For Monitoring And Treating Mesothelioma. <i>Scientific Reports</i> , 2015, 5, 9928.	1.6	37
100	Factors that Determine Sensitivity and Resistances of Tumor Cells Towards Antibody-Targeted Protein Toxins. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2015, , 57-73.	0.1	1
101	Podocyte Injury-Driven Lipid Peroxidation Accelerates the Infiltration of Glomerular Foam Cells in Focal Segmental Glomerulosclerosis. <i>American Journal of Pathology</i> , 2015, 185, 2118-2131.	1.9	39
102	Poor correlation between T-cell activation assays and HLA-DR binding prediction algorithms in an immunogenic fragment of <i>Pseudomonas</i> exotoxin A. <i>Journal of Immunological Methods</i> , 2015, 425, 10-20.	0.6	23
103	Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesothelioma. <i>BMC Cancer</i> , 2015, 15, 376.	1.1	22
104	Characterization of CD22 expression in acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2015, 62, 964-969.	0.8	129
105	Recombinant Immunotoxin with T-cell Epitope Mutations That Greatly Reduce Immunogenicity for Treatment of Mesothelin-Expressing Tumors. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2789-2796.	1.9	34
106	Loss of diphthamide pre-activates NF- κ B and death receptor pathways and renders MCF7 cells hypersensitive to tumor necrosis factor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 10732-10737.	3.3	37
107	High Response Rate of Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia Includes Eradication of Minimal Residual Disease: Potential Importance for Outcome. <i>Blood</i> , 2015, 126, 4161-4161.	0.6	3
108	Moxetumomab pasudotox and minimal residual disease in hairy cell leukemia.. <i>Journal of Clinical Oncology</i> , 2015, 33, 7079-7079.	0.8	1

#	ARTICLE	IF	CITATIONS
109	Methylation-Associated Partial Down-Regulation of Mesothelin Causes Resistance to Anti-Mesothelin Immunotoxins in a Pancreatic Cancer Cell Line. <i>PLoS ONE</i> , 2015, 10, e0122462.	1.1	12
110	Safety and biodistribution of ¹¹¹ In-amatuximab in patients with mesothelin expressing cancers using Single Photon Emission Computed Tomography-Computed Tomography (SPECT-CT) imaging. <i>Oncotarget</i> , 2015, 6, 4496-4504.	0.8	38
111	High mesothelin expression in advanced lung adenocarcinoma is associated with <i>KRAS</i> mutations and a poor prognosis. <i>Oncotarget</i> , 2015, 6, 11694-11703.	0.8	66
112	Twisted Gastrulation, a BMP Antagonist, Exacerbates Podocyte Injury. <i>PLoS ONE</i> , 2014, 9, e89135.	1.1	18
113	Effect of Antigen Shedding on Targeted Delivery of Immunotoxins in Solid Tumors from a Mathematical Model. <i>PLoS ONE</i> , 2014, 9, e110716.	1.1	13
114	Removing T-cell epitopes with computational protein design. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 8577-8582.	3.3	115
115	Phase II Clinical Trial of Amatuximab, a Chimeric Antimesothelin Antibody with Pemetrexed and Cisplatin in Advanced Unresectable Pleural Mesothelioma. <i>Clinical Cancer Research</i> , 2014, 20, 5927-5936.	3.2	158
116	Targeted Cytotoxic Therapy Kills Persisting HIV Infected Cells During ART. <i>PLoS Pathogens</i> , 2014, 10, e1003872.	2.1	101
117	TGF β -PE38 enhances cytotoxic T-lymphocyte killing of breast cancer cells. <i>Oncology Letters</i> , 2014, 7, 2113-2117.	0.8	5
118	Podocyte injury enhances filtration of liver-derived angiotensinogen and renal angiotensin II generation. <i>Kidney International</i> , 2014, 85, 1068-1077.	2.6	58
119	CD21 ^{low} Marginal Zone B Cells Highly Express Fc Receptor-like 5 Protein and Are Killed by Anti-Fc Receptor-like 5 Immunotoxins in Hepatitis C Virus-Associated Mixed Cryoglobulinemia Vasculitis. <i>Arthritis and Rheumatology</i> , 2014, 66, 433-443.	2.9	16
120	Class II human leucocyte antigen DRB1*11 in hairy cell leukaemia patients with and without haemolytic uraemic syndrome. <i>British Journal of Haematology</i> , 2014, 166, 729-738.	1.2	13
121	Combining the Antimesothelin Immunotoxin SS1P With the BH3-mimetic ABT-737 Induces Cell Death in SS1P-resistant Pancreatic Cancer Cells. <i>Journal of Immunotherapy</i> , 2014, 37, 8-15.	1.2	19
122	Efficacy of RG7787, a Next-Generation Mesothelin-Targeted Immunotoxin, against Triple-Negative Breast and Gastric Cancers. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 2653-2661.	1.9	68
123	Immunotoxins for leukemia. <i>Blood</i> , 2014, 123, 2470-2477.	0.6	102
124	Discovery of Mesothelin and Exploiting It as a Target for Immunotherapy. <i>Cancer Research</i> , 2014, 74, 2907-2912.	0.4	204
125	Antitumor Effects of Immunotoxins Are Enhanced by Lowering <i>HCK</i> or Treatment with Src Kinase Inhibitors. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 82-89.	1.9	15
126	Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 8571-8576.	3.3	104

#	ARTICLE	IF	CITATIONS
127	Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for frontâ€line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125. <i>Cancer</i> , 2014, 120, 3311-3319.	2.0	144
128	An improved recombinant Fab-immunotoxin targeting CD22 expressing malignancies. <i>Leukemia Research</i> , 2014, 38, 1224-1229.	0.4	34
129	<i>In Vitro</i> and <i>In Vivo</i> Activity of the Low-Immunogenic Antimesothelin Immunotoxin RG7787 in Pancreatic Cancer. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 2040-2049.	1.9	89
130	Abstract 4510: RG7787 - a novel de-immunized PE based fusion protein for therapy of mesothelin-positive solid tumors. <i>Cancer Research</i> , 2014, 74, 4510-4510.	0.4	3
131	Megakaryocytic Potentiating Factor and Mature Mesothelin Stimulate the Growth of a Lung Cancer Cell Line in the Peritoneal Cavity of Mice. <i>PLoS ONE</i> , 2014, 9, e104388.	1.1	8
132	Mesothelin expression in patients as a novel target in gastric cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 61-61.	0.8	2
133	Anti-CD30 antibody conjugated liposomal doxorubicin with significantly improved therapeutic efficacy against anaplastic large cell lymphoma. <i>Biomaterials</i> , 2013, 34, 8718-8725.	5.7	33
134	Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression. <i>Science Translational Medicine</i> , 2013, 5, 208ra147.	5.8	198
135	A Recombinant Immunotoxin against the Tumor-Associated Antigen Mesothelin Reengineered for High Activity, Low Off-Target Toxicity, and Reduced Antigenicity. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 48-57.	1.9	87
136	Methylation of the DPH1 promoter causes immunotoxin resistance in acute lymphoblastic leukemia cell line KOPN-8. <i>Leukemia Research</i> , 2013, 37, 1551-1556.	0.4	22
137	Aberrant Notch1-dependent effects on glomerular parietal epithelial cells promotes collapsing focal segmental glomerulosclerosis with progressive podocyte loss. <i>Kidney International</i> , 2013, 83, 1065-1075.	2.6	57
138	A Modified Form of Diphthamide Causes Immunotoxin Resistance in a Lymphoma Cell Line with a Deletion of the WDR85 Gene. <i>Journal of Biological Chemistry</i> , 2013, 288, 12305-12312.	1.6	28
139	The Insulin Receptor Negatively Regulates the Action of <i>Pseudomonas</i> Toxin-Based Immunotoxins and Native <i>Pseudomonas</i> Toxin. <i>Cancer Research</i> , 2013, 73, 2281-2288.	0.4	17
140	Identification and Enhancement of HLA-A2.1-Restricted CTL Epitopes in a New Human Cancer Antigen-POTE. <i>PLoS ONE</i> , 2013, 8, e64365.	1.1	15
141	Pharmacokinetic Analysis Of Response In Hairy Cell Leukemia Treated By Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox. <i>Blood</i> , 2013, 122, 2871-2871.	0.6	4
142	Combination Treatments with the PKC Inhibitor, Enzastaurin, Enhance the Cytotoxicity of the Anti-Mesothelin Immunotoxin, SS1P. <i>PLoS ONE</i> , 2013, 8, e75576.	1.1	13
143	A recombinant immunotoxin engineered for increased stability by adding a disulfide bond has decreased immunogenicity. <i>Protein Engineering, Design and Selection</i> , 2012, 25, 1-6.	1.0	30
144	Recognition of Mesothelin by the Therapeutic Antibody MORAb-009. <i>Journal of Biological Chemistry</i> , 2012, 287, 33123-33131.	1.6	33

#	ARTICLE	IF	CITATIONS
145	Targeting malignant B cells with an immunotoxin against ROR1. <i>MAbs</i> , 2012, 4, 349-361.	2.6	59
146	Toxin-Based Targeted Therapy for Malignant Brain Tumors. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-15.	3.3	24
147	Characterization of crystals of an antibody-recognition fragment of the cancer differentiation antigen mesothelin in complex with the therapeutic antibody MORAb-009. <i>Acta Crystallographica Section F: Structural Biology Communications</i> , 2012, 68, 950-953.	0.7	8
148	Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based on <i>Pseudomonas</i> exotoxin A. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, E3597-603.	3.3	89
149	Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 11782-11787.	3.3	145
150	Antigen Shedding May Improve Efficiencies for Delivery of Antibody-Based Anticancer Agents in Solid Tumors. <i>Cancer Research</i> , 2012, 72, 3143-3152.	0.4	40
151	Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 6898-6903.	3.3	49
152	Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia. <i>Journal of Clinical Oncology</i> , 2012, 30, 1822-1828.	0.8	287
153	Mesothelin-Targeted Agents in Clinical Trials and in Preclinical Development. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 517-525.	1.9	96
154	Synergistic Antitumor Activity of Anti-CD25 Recombinant Immunotoxin LMB-2 with Chemotherapy. <i>Clinical Cancer Research</i> , 2012, 18, 152-160.	3.2	19
155	Pulsed high intensity focused ultrasound increases penetration and therapeutic efficacy of monoclonal antibodies in murine xenograft tumors. <i>Journal of Controlled Release</i> , 2012, 162, 218-224.	4.8	64
156	POTE protein, a cancer-testis antigen, is highly expressed in spermatids in human testis and is associated with apoptotic cells. <i>Biochemical and Biophysical Research Communications</i> , 2012, 417, 1271-1274.	1.0	15
157	ANKRD26 and Its Interacting Partners TRIO, GPS2, HMMR and DIPA Regulate Adipogenesis in 3T3-L1 Cells. <i>PLoS ONE</i> , 2012, 7, e38130.	1.1	28
158	Resolution of Hairy Cell Leukemia Minimal Residual Disease by Both BRAF and Clone-Specific Real-Time Quantitative PCR (RQ-PCR) After Treatment with Moxetumomab Pasudotox.. <i>Blood</i> , 2012, 120, 2896-2896.	0.6	1
159	Efficiency of Immunotoxin Cytotoxicity Is Modulated by the Intracellular Itinerary. <i>PLoS ONE</i> , 2012, 7, e47320.	1.1	12
160	Modulating Mesothelin Shedding to Improve Therapy. <i>Oncotarget</i> , 2012, 3, 114-115.	0.8	13
161	Convection Enhanced Delivery of Macromolecules for Brain Tumors. <i>Current Drug Discovery Technologies</i> , 2012, 9, 305-310.	0.6	29
162	Durability of complete remission by moxetumomab pasudotox (HA22 or CAT-8015) assessed by clone-specific real-time quantitative PCR (RQ-PCR).. <i>Journal of Clinical Oncology</i> , 2012, 30, 2503-2503.	0.8	0

#	ARTICLE	IF	CITATIONS
163	Decreased Expression of Diphthamide Genes Is Responsible for the Resistance to the Anti-CD22 Immunotoxin Moxetumomab Pasudotox (m. pasudotox) in Acute Lymphoblastic Leukemia (ALL)/Non-Hodgkin Lymphoma (NHL) Cell Lines.. Blood, 2012, 120, 2443-2443.	0.6	0
164	The HLA-DRB1*11 Antigen Is Preferentially Expressed in Hairy Cell Leukemia, Particularly in Patients Who Had Hemolytic Uremic Syndrome with Recombinant Immunotoxin BL22.. Blood, 2012, 120, 2488-2488.	0.6	0
165	A New High Activity Anti-CD22 Chimeric Antigen Receptor (CAR) Targeting B Cell Leukemia.. Blood, 2012, 120, 2611-2611.	0.6	0
166	Loss of mesothelin expression by mesothelioma cells grown in vitro determines sensitivity to anti-mesothelin immunotoxin SS1P. Anticancer Research, 2012, 32, 5151-8.	0.5	18
167	Enhancing immunotoxin cell-killing activity via combination therapy with ABT-737. Leukemia and Lymphoma, 2011, 52, 79-81.	0.6	15
168	Immunotoxins with decreased immunogenicity and improved activity. Leukemia and Lymphoma, 2011, 52, 87-90.	0.6	20
169	Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox. Clinical Cancer Research, 2011, 17, 6398-6405.	3.2	201
170	Treatment of Hematologic Malignancies with Immunotoxins and Antibody-Drug Conjugates. Cancer Research, 2011, 71, 6300-6309.	0.4	119
171	Exploiting bias in a non-immune human antibody library to predict antigenicity. Protein Engineering, Design and Selection, 2011, 24, 845-853.	1.0	1
172	Imaging of Convection Enhanced Delivery of Toxins in Humans. Toxins, 2011, 3, 201-206.	1.5	20
173	A guide to taming a toxinâ€”recombinant immunotoxins constructed from <i>Pseudomonas</i> exotoxin A for the treatment of cancer. FEBS Journal, 2011, 278, 4683-4700.	2.2	209
174	Killing of Resistant Cancer Cells with Low Bak by a Combination of an Antimesothelin Immunotoxin and a TRAIL Receptor 2 Agonist Antibody. Clinical Cancer Research, 2011, 17, 5926-5934.	3.2	21
175	A novel highâ€”affinity human monoclonal antibody to mesothelin. International Journal of Cancer, 2011, 128, 2020-2030.	2.3	52
176	Affinityâ€”matured antiâ€”glycoprotein NMB recombinant immunotoxins targeting malignant gliomas and melanomas. International Journal of Cancer, 2011, 129, 111-121.	2.3	23
177	The improvement of an anti-CD22 immunotoxin. MAbs, 2011, 3, 479-486.	2.6	15
178	Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia. Leukemia and Lymphoma, 2011, 52, 82-86.	0.6	23
179	Ankrd26 Gene Disruption Enhances Adipogenesis of Mouse Embryonic Fibroblasts*. Journal of Biological Chemistry, 2011, 286, 27761-27768.	1.6	57
180	Pentostatin Plus Cyclophosphamide Safely and Effectively Prevents Immunotoxin Immunogenicity in Murine Hosts. Clinical Cancer Research, 2011, 17, 3697-3705.	3.2	44

#	ARTICLE	IF	CITATIONS
181	Podocyte Injury Damages Other Podocytes. Journal of the American Society of Nephrology: JASN, 2011, 22, 1275-1285.	3.0	98
182	Cytotoxic Activity of Immunotoxin SS1P Is Modulated by TACE-Dependent Mesothelin Shedding. Cancer Research, 2011, 71, 5915-5922.	0.4	31
183	Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 5742-5747.	3.3	97
184	A Novel Anti-CD22 Immunotoxin, Moxetumomab Pasudotox: Phase I Study in Pediatric Acute Lymphoblastic Leukemia (ALL). Blood, 2011, 118, 248-248.	0.6	37
185	Regression of Adult T-Cell Leukemia with Anti-CD25 Recombinant Immunotoxin LMB-2 Preceded by Chemotherapy. Blood, 2011, 118, 2575-2575.	0.6	3
186	Advances in the Development of Anti-CD22 Immunotoxins Containing Pseudomonas Exotoxin for Treatment of Hematologic Malignancies. Journal of Cancer Science & Therapy, 2011, 03, .	1.7	8
187	A Recombinant Immunotoxin Targeting CD22 With Low Immunogenicity, Low Nonspecific Toxicity, and High Antitumor Activity in Mice. Journal of Immunotherapy, 2010, 33, 297-304.	1.2	35
188	Convection-enhanced delivery of free gadolinium with the recombinant immunotoxin MR1-1. Journal of Neuro-Oncology, 2010, 98, 1-7.	1.4	46
189	Immunotoxin BL22 induces apoptosis in mantle cell lymphoma (MCL) cells dependent on Bcl-2 expression. British Journal of Haematology, 2010, 148, 99-109.	1.2	23
190	Cytotoxicity of the anti-CD22 immunotoxin HA22 (CAT-8015) against paediatric acute lymphoblastic leukaemia. British Journal of Haematology, 2010, 150, 352-358.	1.2	69
191	Phase I Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody MORAb-009 in Patients with Mesothelin-Expressing Cancers. Clinical Cancer Research, 2010, 16, 6132-6138.	3.2	190
192	Anti-CD22 Immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-Positive Hematologic Malignancies of Childhood: Preclinical Studies and Phase I Clinical Trial. Clinical Cancer Research, 2010, 16, 1894-1903.	3.2	139
193	Pseudomonas Exotoxin A-Mediated Apoptosis Is Bcl-2 Dependent and Preceded by the Degradation of Mcl-1. Molecular and Cellular Biology, 2010, 30, 3444-3452.	1.1	63
194	Interstitial Infusion of Glioma-Targeted Recombinant Immunotoxin 8H9scFv-PE38. Molecular Cancer Therapeutics, 2010, 9, 1039-1046.	1.9	31
195	Immunotoxin Complementation of HAART to Deplete Persisting HIV-Infected Cell Reservoirs. PLoS Pathogens, 2010, 6, e1000803.	2.1	43
196	A Flow Cytometry Method to Quantitate Internalized Immunotoxins Shows that Taxol Synergistically Increases Cellular Immunotoxins Uptake. Cancer Research, 2010, 70, 1082-1089.	0.4	38
197	Recombinant Immunotoxins for Treating Cancer. , 2010, , 127-146.		8
198	Complete Remissions In 3 of 12 Patients with Pediatric Acute Lymphoblastic Leukemia (ALL) During Phase I Testing of the Anti-CD22 Immunotoxin Moxetumomab Pasudotox. Blood, 2010, 116, 3246-3246.	0.6	3

#	ARTICLE	IF	CITATIONS
199	Approach to the patient after relapse of hairy cell leukemia. <i>Leukemia and Lymphoma</i> , 2009, 50, 32-37.	0.6	14
200	Phase II Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With Hairy Cell Leukemia. <i>Journal of Clinical Oncology</i> , 2009, 27, 2983-2990.	0.8	208
201	CAT-8015: A Second-Generation Pseudomonas Exotoxin A-Based Immunotherapy Targeting CD22-Expressing Hematologic Malignancies. <i>Clinical Cancer Research</i> , 2009, 15, 832-839.	3.2	107
202	Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P. <i>Clinical Cancer Research</i> , 2009, 15, 5274-5279.	3.2	209
203	A primate-specific POTE-actin fusion protein plays a role in apoptosis. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2009, 14, 1237-1244.	2.2	38
204	Removal of B cell epitopes as a practical approach for reducing the immunogenicity of foreign protein-based therapeutics. <i>Advanced Drug Delivery Reviews</i> , 2009, 61, 977-985.	6.6	73
205	Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 3360-3365.	3.3	758
206	A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity. <i>Blood</i> , 2009, 113, 3792-3800.	0.6	174
207	Long Term Results of BL22 (CAT-3888) in Multiply Relapsed Hairy Cell Leukemia. <i>Blood</i> , 2009, 114, 3442-3442.	0.6	1
208	Phase I Clinical Trial of the Anti-CD22 Immunotoxin CAT-8015 (HA22) for Pediatric Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2009, 114, 839-839.	0.6	7
209	Phase I Dose-Escalation Study of CAT-8015 (HA22), A CD22-Specific Targeted Immunotoxin, in Relapsed or Refractory Hairy Cell Leukemia. <i>Blood</i> , 2009, 114, 888-888.	0.6	7
210	Expression of POTE protein in human testis detected by novel monoclonal antibodies. <i>Biochemical and Biophysical Research Communications</i> , 2008, 365, 603-608.	1.0	14
211	An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 11311-11316.	3.3	157
212	High Shed Antigen Levels within Tumors: An Additional Barrier to Immunoconjugate Therapy. <i>Clinical Cancer Research</i> , 2008, 14, 7981-7986.	3.2	59
213	Differential Cellular Internalization of Anti-CD19 and -CD22 Immunotoxins Results in Different Cytotoxic Activity. <i>Cancer Research</i> , 2008, 68, 6300-6305.	0.4	111
214	Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. <i>Neuro-Oncology</i> , 2008, 10, 320-329.	0.6	179
215	Topology of NGEF, a Prostate-Specific Cell:Cell Junction Protein Widely Expressed in Many Cancers of Different Grade Level. <i>Cancer Research</i> , 2008, 68, 6306-6312.	0.4	64
216	A model for obesity and gigantism due to disruption of the Ankrd26 gene. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 270-275.	3.3	79

#	ARTICLE	IF	CITATIONS
217	Selective POTE Paralogs on Chromosome 2 are Expressed in Human Embryonic Stem Cells. <i>Stem Cells and Development</i> , 2008, 17, 325-332.	1.1	19
218	FCRL1 on chronic lymphocytic leukemia, hairy cell leukemia, and B-cell non-Hodgkin lymphoma as a target of immunotoxins. <i>Blood</i> , 2008, 111, 338-343.	0.6	41
219	IL-2 nonresponsive subset of human natural regulatory T cells expresses Fc receptor-like 3 protein. <i>FASEB Journal</i> , 2008, 22, 381-381.	0.2	0
220	Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 17099-17104.	3.3	75
221	Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers. <i>Clinical Cancer Research</i> , 2007, 13, 5144-5149.	3.2	351
222	Induction of Hyperintense Signal on T2-Weighted MR Images Correlates with Infusion Distribution from Intracerebral Convection-Enhanced Delivery of a Tumor-Targeted Cytotoxin. <i>American Journal of Roentgenology</i> , 2007, 188, 703-709.	1.0	67
223	Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions. <i>Neuro-Oncology</i> , 2007, 9, 343-353.	0.6	112
224	Administration of a CD25-Directed Immunotoxin, LMB-2, to Patients with Metastatic Melanoma Induces a Selective Partial Reduction in Regulatory T Cells In Vivo. <i>Journal of Immunology</i> , 2007, 179, 4919-4928.	0.4	162
225	Mesothelin Expression in Human Lung Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 1571-1575.	3.2	118
226	Intracerebral Infusate Distribution by Convection-enhanced Delivery in Humans with Malignant Gliomas: Descriptive Effects of Target Anatomy and Catheter Positioning. <i>Operative Neurosurgery</i> , 2007, 60, ONS-89-ONS-99.	0.4	95
227	New Immunotoxins Targeting CD123, a Stem Cell Antigen on Acute Myeloid Leukemia Cells. <i>Journal of Immunotherapy</i> , 2007, 30, 607-613.	1.2	102
228	Palmitoylation of POTE family proteins for plasma membrane targeting. <i>Biochemical and Biophysical Research Communications</i> , 2007, 363, 751-756.	1.0	7
229	Immunotoxin Treatment of Cancer*. <i>Annual Review of Medicine</i> , 2007, 58, 221-237.	5.0	340
230	Targeting CD22 in Childhood B-Precursor Acute Lymphoblastic Leukemia (Pre-B ALL): Pre-Clinical Studies and Phase I Trial of the Anti-CD22 Immunotoxin CAT-3888 (BL22).. <i>Blood</i> , 2007, 110, 855-855.	0.6	1
231	Pre-Clinical Evaluation of the Anti-CD22 Immunotoxin CAT-8015 in Combination with Chemotherapy Agents for Childhood B-Precursor Acute Lymphoblastic Leukemia (Pre-B ALL).. <i>Blood</i> , 2007, 110, 865-865.	0.6	5
232	Immunotoxins in the Treatment of Refractory Hairy Cell Leukemia. <i>Hematology/Oncology Clinics of North America</i> , 2006, 20, 1137-1151.	0.9	20
233	Detection and Quantitation of Serum Mesothelin, a Tumor Marker for Patients with Mesothelioma and Ovarian Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 447-453.	3.2	256
234	Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. <i>Molecular Cancer</i> , 2006, 5, 50.	7.9	325

#	ARTICLE	IF	CITATIONS
235	Selective Elimination of Human Regulatory T Lymphocytes In Vitro With the Recombinant Immunotoxin LMB-2. <i>Journal of Immunotherapy</i> , 2006, 29, 208-214.	1.2	66
236	Immunotoxin therapy of cancer. <i>Nature Reviews Cancer</i> , 2006, 6, 559-565.	12.8	475
237	Immunotoxins in the Treatment of Hematologic Malignancies. <i>Current Drug Targets</i> , 2006, 7, 1301-1311.	1.0	75
238	Anti-HIV-1 immunotoxin 3B3(Fv)-PE38: enhanced potency against clinical isolates in human PBMCs and macrophages, and negligible hepatotoxicity in macaques. <i>Journal of Leukocyte Biology</i> , 2006, 80, 1175-1182.	1.5	27
239	Megakaryocyte Potentiation Factor Cleaved from Mesothelin Precursor Is a Useful Tumor Marker in the Serum of Patients with Mesothelioma. <i>Clinical Cancer Research</i> , 2006, 12, 4225-4231.	3.2	101
240	Evolution and expression of chimeric POTE-actin genes in the human genome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 17885-17890.	3.3	42
241	Sandwich ELISAs for soluble immunoglobulin superfamily receptor translocation-associated 2 (IRTA2)/FcRH5 (CD307) proteins in human sera. <i>Clinical Chemistry and Laboratory Medicine</i> , 2006, 44, 594-602.	1.4	6
242	POTE Paralogs Are Induced and Differentially Expressed in Many Cancers. <i>Cancer Research</i> , 2006, 66, 52-56.	0.4	59
243	Characterization of the B Cell Epitopes Associated with a Truncated Form of <i>Pseudomonas</i> Exotoxin (PE38) Used to Make Immunotoxins for the Treatment of Cancer Patients. <i>Journal of Immunology</i> , 2006, 177, 8822-8834.	0.4	104
244	Synergistic Antitumor Activity of Taxol and Immunotoxin SS1P in Tumor-Bearing Mice. <i>Clinical Cancer Research</i> , 2006, 12, 4695-4701.	3.2	73
245	Localization of Mesothelin in Epithelial Ovarian Cancer. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2005, 13, 243-247.	0.6	152
246	Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: Case study. <i>Neuro-Oncology</i> , 2005, 7, 90-96.	0.6	54
247	In Vitro Antibody Evolution Targeting Germline Hot Spots to Increase Activity of an Anti-CD22 Immunotoxin. <i>Journal of Biological Chemistry</i> , 2005, 280, 607-617.	1.6	96
248	Genetic Engineering of Glomerular Sclerosis in the Mouse via Control of Onset and Severity of Podocyte-Specific Injury. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 1013-1023.	3.0	225
249	New Monoclonal Antibodies to Mesothelin Useful for Immunohistochemistry, Fluorescence-Activated Cell Sorting, Western Blotting, and ELISA. <i>Clinical Cancer Research</i> , 2005, 11, 5840-5846.	3.2	65
250	An NIH Career: from Bedside to Basic Research and Back. <i>Journal of Biological Chemistry</i> , 2005, 280, 18553-18557.	1.6	1
251	Humoral Immune Response to Mesothelin in Mesothelioma and Ovarian Cancer Patients. <i>Clinical Cancer Research</i> , 2005, 11, 3814-3820.	3.2	140
252	Phase I Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With B-Cell Malignancies. <i>Journal of Clinical Oncology</i> , 2005, 23, 6719-6729.	0.8	262

#	ARTICLE	IF	CITATIONS
253	HA22 (R490A) Is a Recombinant Immunotoxin with Increased Antitumor Activity without an Increase in Animal Toxicity. <i>Clinical Cancer Research</i> , 2005, 11, 1545-1550.	3.2	78
254	Recombinant Immunotoxins in the Treatment of Cancer. , 2004, 248, 503-518.		70
255	Mesothelin. <i>Clinical Cancer Research</i> , 2004, 10, 3937-3942.	3.2	394
256	The T Cell Receptor β Chain Alternate Reading Frame Protein (TARP), a Prostate-specific Protein Localized in Mitochondria. <i>Journal of Biological Chemistry</i> , 2004, 279, 24561-24568.	1.6	25
257	Pretreatment with Rituximab Does Not Inhibit the Human Immune Response against the Immunogenic Protein LMB-1. <i>Clinical Cancer Research</i> , 2004, 10, 16-18.	3.2	51
258	Rapid grouping of monoclonal antibodies based on their topographical epitopes by a label-free competitive immunoassay. <i>Journal of Immunological Methods</i> , 2004, 292, 141-155.	0.6	24
259	Five POTE paralogs and their splice variants are expressed in human prostate and encode proteins of different lengths. <i>Gene</i> , 2004, 337, 45-53.	1.0	43
260	Recombinant immunotoxins for treating cancer. <i>International Journal of Medical Microbiology</i> , 2004, 293, 577-582.	1.5	81
261	Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxins. <i>Blood</i> , 2004, 103, 2718-2726.	0.6	64
262	BL22, a Recombinant Anti-CD22 Immunotoxin, Induces Cell Cycle Arrest and Apoptosis in B-Cell Lymphoma.. <i>Blood</i> , 2004, 104, 4613-4613.	0.6	1
263	Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. <i>Journal of Neuro-Oncology</i> , 2003, 65, 27-35.	1.4	222
264	Immunotoxins containing Pseudomonas exotoxin A: a short history. <i>Cancer Immunology, Immunotherapy</i> , 2003, 52, 338-341.	2.0	88
265	DNA immunization followed by a single boost with cells: a protein-free immunization protocol for production of monoclonal antibodies against the native form of membrane proteins. <i>Journal of Immunological Methods</i> , 2003, 280, 59-72.	0.6	43
266	PATE, a gene expressed in prostate cancer, normal prostate, and testis, identified by a functional genomic approach. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 3058-3063.	3.3	38
267	POTE, a highly homologous gene family located on numerous chromosomes and expressed in prostate, ovary, testis, placenta, and prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 16975-16980.	3.3	75
268	Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display. <i>Clinical Cancer Research</i> , 2002, 8, 995-1002.	3.2	135
269	Novel anti-CD30 recombinant immunotoxins containing disulfide-stabilized Fv fragments. <i>Clinical Cancer Research</i> , 2002, 8, 2345-55.	3.2	32
270	Immunotoxins in cancer therapy. <i>Current Opinion in Investigational Drugs</i> , 2002, 3, 1089-91.	2.3	12

#	ARTICLE	IF	CITATIONS
271	Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro. <i>Clinical Cancer Research</i> , 2002, 8, 3520-6.	3.2	60
272	Efficacy of the Anti-CD22 Recombinant Immunotoxin BL22 in Chemotherapy-Resistant Hairy-Cell Leukemia. <i>New England Journal of Medicine</i> , 2001, 345, 241-247.	13.9	509
273	PRAC: A novel small nuclear protein that is specifically expressed in human prostate and colon. <i>Prostate</i> , 2001, 47, 125-131.	1.2	36
274	GDEP, a new gene differentially expressed in normal prostate and prostate cancer. <i>Prostate</i> , 2001, 48, 231-241.	1.2	31
275	Efficient ablation by immunotoxin-mediated cell targeting of the cell types that express human interleukin-2 receptor depending on the internal ribosome entry site. <i>Journal of Gene Medicine</i> , 2001, 3, 505-510.	1.4	8
276	Isolation of new anti-CD30 scFvs from DNA-immunized mice by phage display and biologic activity of recombinant immunotoxins produced by fusion with truncated pseudomonas exotoxin. <i>International Journal of Cancer</i> , 2001, 92, 861-870.	2.3	22
277	Designed heterodimerizing leucine zippers with a range of pIs and stabilities up to 10-15 M. <i>Protein Science</i> , 2001, 10, 649-655.	3.1	130
278	Cse11 Is Essential for Early Embryonic Growth and Development. <i>Molecular and Cellular Biology</i> , 2001, 21, 7020-7024.	1.1	32
279	Phase I Trial of Recombinant Immunotoxin Anti-Tac(Fv)-PE38 (LMB-2) in Patients With Hematologic Malignancies. <i>Journal of Clinical Oncology</i> , 2000, 18, 1622-1636.	0.8	416
280	Anti-Tumor Activity of K1-LysPE38QQR, an Immunotoxin Targeting Mesothelin, a Cell-Surface Antigen Overexpressed in Ovarian Cancer and Malignant Mesothelioma. <i>Journal of Immunotherapy</i> , 2000, 23, 473-479.	1.2	60
281	Apoptosis induced by immunotoxins used in the treatment of hematologic malignancies. <i>International Journal of Cancer</i> , 2000, 87, 86-94.	2.3	70
282	Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII-specific scFv. <i>International Journal of Cancer</i> , 2000, 88, 962-969.	2.3	68
283	Attenuating the growth of tumors by intratumoral administration of DNA encoding Pseudomonas exotoxin via cationic liposomes. <i>Cancer Gene Therapy</i> , 2000, 7, 91-96.	2.2	21
284	Decreased accumulation of [14c]carboplatin in human cisplatin-resistant cells results from reduced energy-dependent uptake. <i>Journal of Cellular Physiology</i> , 2000, 183, 108-116.	2.0	91
285	Inhibition of TNF- α Produced by Kupffer Cells Protects Against the Nonspecific Liver Toxicity of Immunotoxin Anti-Tac(Fv)-PE38, LMB-2. <i>Journal of Immunology</i> , 2000, 165, 7150-7156.	0.4	59
286	Mesothelin Is Not Required for Normal Mouse Development or Reproduction. <i>Molecular and Cellular Biology</i> , 2000, 20, 2902-2906.	1.1	198
287	Decreased accumulation of [14c]carboplatin in human cisplatin-resistant cells results from reduced energy-dependent uptake. , 2000, 183, 108.		2
288	Responses in Refractory Hairy Cell Leukemia to a Recombinant Immunotoxin. <i>Blood</i> , 1999, 94, 3340-3348.	0.6	161

#	ARTICLE	IF	CITATIONS
289	Interleukin-4 receptor-directed cytotoxin therapy of AIDS-associated Kaposi's sarcoma tumors in xenograft model. <i>Nature Medicine</i> , 1999, 5, 817-822.	15.2	44
290	Improving antibody affinity by mimicking somatic hypermutation in vitro. <i>Nature Biotechnology</i> , 1999, 17, 568-572.	9.4	238
291	Expression profile of saccharide epitope CaMBr1 in normal and neoplastic tissue from dogs, cats, and rats: implication for the development of human-derived cancer vaccines. <i>The Histochemical Journal</i> , 1999, 31, 729-737.	0.6	4
292	BIOCHEMICAL, CELLULAR, AND PHARMACOLOGICAL ASPECTS OF THE MULTIDRUG TRANSPORTER. <i>Annual Review of Pharmacology and Toxicology</i> , 1999, 39, 361-398.	4.2	1,940
293	¹¹¹ Indium-labeled monoclonal antibody K1: Biodistribution study in nude mice bearing a human carcinoma xenograft expressing mesothelin. , 1999, 80, 559-563.		33
294	Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys. , 1999, 81, 148-155.		81
295	A Single Amino Acid Residue Contributes to Distinct Mechanisms of Inhibition of the Human Multidrug Transporter by Stereoisomers of the Dopamine Receptor Antagonist Flupentixol. <i>Biochemistry</i> , 1999, 38, 6630-6639.	1.2	60
296	Both ATP Sites of Human P-Glycoprotein Are Essential but Not Symmetric. <i>Biochemistry</i> , 1999, 38, 13887-13899.	1.2	137
297	Chemical Modification to Reduce Renal Uptake of Disulfide-Bonded Variable Region Fragment of Anti-Tac Monoclonal Antibody Labeled with ^{99m} Tc. <i>Bioconjugate Chemistry</i> , 1999, 10, 447-453.	1.8	19
298	Epitope Blocking: Positive and Negative Effects on the Biodistribution of ¹²⁵ I-Labeled Anti-Tac Disulfide-stabilized Fv Fragment of Two Antibodies against Different Epitopes of the Circulating Antigen. <i>Japanese Journal of Cancer Research</i> , 1998, 89, 436-444.	1.7	1
299	Anti-prostate immunotoxins: Cytotoxicity of E4 antibody- <i>Pseudomonas</i> exotoxin constructs. , 1998, 77, 123-127.		9
300	Autonomic neuropathy in transgenic mice caused by immunotoxin targeting of the peripheral nervous system. , 1998, 51, 162-173.		12
301	Expression of Lewis carbohydrate antigens in metastatic lesions from human prostatic carcinoma. , 1998, 36, 162-167.		11
302	Crystal structure of the disulfide-stabilized Fv fragment of anticancer antibody B1: Conformational influence of an engineered disulfide bond. <i>Proteins: Structure, Function and Bioinformatics</i> , 1998, 31, 128-138.	1.5	26
303	Human P-Glycoprotein Exhibits Reduced Affinity for Substrates during a Catalytic Transition State. <i>Biochemistry</i> , 1998, 37, 5010-5019.	1.2	245
304	Comparison of Recombinant Immunotoxins against LeY Antigen Expressing Tumor Cells: Influence of Affinity, Size, and Stability. <i>Bioconjugate Chemistry</i> , 1998, 9, 736-743.	1.8	17
305	A bivalent disulfide-stabilized fv with improved antigen binding to erbB2. <i>Journal of Molecular Biology</i> , 1998, 281, 475-483.	2.0	35
306	Contribution to Substrate Specificity and Transport of Nonconserved Residues in Transmembrane Domain 12 of Human P-Glycoprotein. <i>Biochemistry</i> , 1998, 37, 16400-16409.	1.2	80

#	ARTICLE	IF	CITATIONS
307	Structural Flexibility of the Linker Region of Human P-Glycoprotein Permits ATP Hydrolysis and Drug Transport. <i>Biochemistry</i> , 1998, 37, 13660-13673.	1.2	99
308	Antisense Inhibition of CAS, the Human Homologue of the Yeast Chromosome Segregation Gene CSE1, Interferes with Mitosis in HeLa Cells. <i>Biochemistry</i> , 1997, 36, 9493-9500.	1.2	29
309	Interleukin-13 Receptors on Human Prostate Carcinoma Cell Lines Represent a Novel Target for a Chimeric Protein Composed of IL-13 and a Mutated Form of Pseudomonas Exotoxin. <i>Journal of Urology</i> , 1997, 158, 948-953.	0.2	56
310	Isolation of anti-mesothelin antibodies from a phage display library. <i>Molecular Immunology</i> , 1997, 34, 9-20.	1.0	25
311	Recombinant RFB4 Immunotoxins Exhibit Potent Cytotoxic Activity for CD22-Bearing Cells and Tumors. <i>Blood</i> , 1997, 90, 2020-2026.	0.6	112
312	Sensitivity of human acute myeloid leukaemia to diphtheria toxin-GM-CSF fusion protein. <i>British Journal of Haematology</i> , 1997, 98, 952-959.	1.2	6
313	Identification of epitopes on a mutant form of Pseudomonas exotoxin using serum from humans treated with Pseudomonas exotoxin containing immunotoxins. <i>European Journal of Immunology</i> , 1997, 27, 1459-1468.	1.6	31
314	Cloning and expression of the recombinant FAb fragment of monoclonal antibody K1 that reacts with mesothelin present on mesotheliomas and ovarian cancers. , 1997, 71, 638-644.		14
315	Amphiregulin antisense oligonucleotide inhibits the growth of T3M4 human pancreatic cancer cells and sensitizes the cells to EGF receptor-targeted therapy. , 1997, 72, 512-517.		51
316	Role of CAS, a Human Homologue to the Yeast Chromosome Segregation Gene CSE1, in Toxin and Tumor Necrosis Factor Mediated Apoptosis. <i>Biochemistry</i> , 1996, 35, 6891-6899.	1.2	83
317	Studies on the Activity of Barnase Toxin in Vitro and in Vivo. <i>Bioconjugate Chemistry</i> , 1996, 7, 23-29.	1.8	22
318	Recombinant immunotoxins. <i>Breast Cancer Research and Treatment</i> , 1996, 38, 3-9.	1.1	18
319	Recombinant single-chain and disulfide-stabilized Fv-immunotoxins that cause complete regression of a human colon cancer xenograft in nude mice. , 1996, 67, 113-123.		21
320	Engineering antibody Fv fragments for cancer detection and therapy: Disulfide-stabilized Fv fragments. <i>Nature Biotechnology</i> , 1996, 14, 1239-1245.	9.4	143
321	Treatment of advanced solid tumors with immunotoxin LMB-1: An antibody linked to Pseudomonas exotoxin. <i>Nature Medicine</i> , 1996, 2, 350-353.	15.2	206
322	Administration of disulfide-stabilized Fv-immunotoxins B1(dsFv)-PE38 and B3(dsFv)-PE38 by continuous infusion increases their efficacy in curing large tumor xenografts in nude mice. <i>International Journal of Cancer</i> , 1995, 62, 351-355.	2.3	34
323	Targeting Pseudomonas exotoxin to hematologic malignancies. <i>Seminars in Cancer Biology</i> , 1995, 6, 297-306.	4.3	52
324	Expression Cloning of cDNAs That Render Cancer Cells Resistant to Pseudomonas and Diphtheria Toxin and Immunotoxins. <i>Molecular Medicine</i> , 1995, 1, 206-216.	1.9	44

#	ARTICLE	IF	CITATIONS
325	Identification of Residues That Stabilize the Single-chain Fv of Monoclonal Antibodies B3. <i>Journal of Biological Chemistry</i> , 1995, 270, 23373-23380.	1.6	29
326	Engineering interchain disulfide bonds into conserved framework regions of Fv fragments: improved biochemical characteristics of recombinant immunotoxins containing disulfide-stabilized Fv. <i>Protein Engineering, Design and Selection</i> , 1994, 7, 697-704.	1.0	94
327	Comparative biodistribution of indium- and yttrium-labeled B3 monoclonal antibody conjugated to either 2-(p-SCN-Bz)-6-methyl-DTPA (1 B4M-DTPA) or 2-(p-SCN-Bz)-1,4,7,10-tetraazacyclododecane tetraacetic acid (2B-DOTA). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1994, 21, 640-646.	2.2	40
328	Design of interchain disulfide bonds in the framework region of the Fv fragment of the monoclonal antibody B3. <i>Proteins: Structure, Function and Bioinformatics</i> , 1994, 19, 35-47.	1.5	54
329	Putative α -MDR enhancer is located on human chromosome 20 and not linked to the MDRI gene on chromosome 7. <i>Genes Chromosomes and Cancer</i> , 1994, 10, 267-274.	1.5	7
330	Molecular cloning and expression of a cDNA encoding a protein detected by the ki antibody from an ovarian carcinoma (OVCAR-3) cell line. <i>International Journal of Cancer</i> , 1994, 57, 90-97.	2.3	44
331	Anti-Tac(Fab)-PE40, a recombinant double-chain immunotoxin which kills interleukin-2-receptor-bearing cells and induces complete remission in an in vivo tumor model. <i>International Journal of Cancer</i> , 1994, 57, 856-864.	2.3	25
332	Cytotoxic and antitumor activity of a recombinant immunotoxin composed of disulfide-stabilized anti-TAC Fv fragment and truncated pseudomonas exotoxin. <i>International Journal of Cancer</i> , 1994, 58, 142-149.	2.3	44
333	Human neurological cancer cells express interleukin-4 (IL-4) receptors which are targets for the toxic effects of IL4-pseudomonas exotoxin chimeric protein. <i>International Journal of Cancer</i> , 1994, 58, 574-581.	2.3	112
334	Interleukin-4 receptors expressed on tumor cells may serve as a target for anticancer therapy using chimeric Pseudomonas exotoxin. <i>International Journal of Cancer</i> , 1994, 58, 744-748.	2.3	20
335	Cytotoxic effect of a fusion protein from transforming growth factor and Pseudomonas exotoxin on rat and human bladder carcinoma cells in vitro. <i>Journal of Cancer Research and Clinical Oncology</i> , 1994, 120, 507-512.	1.2	6
336	Efficient Expression of Drug-selectable Genes in Retroviral Vectors Under Control of an Internal Ribosome Entry Site. <i>Nature Biotechnology</i> , 1994, 12, 694-698.	9.4	58
337	Domain II of Pseudomonas Exotoxin A Arrests the Transfer of Translocating Nascent Chains into Mammalian Microsomes. <i>Biochemistry</i> , 1994, 33, 5894-5900.	1.2	37
338	Interleukin 6 Receptor mRNA in Prostate Carcinomas and Benign Prostate Hyperplasia. <i>Journal of Urology</i> , 1994, 151, 1396-1399.	0.2	80
339	Characterization of an unusual mutant of human melanoma cells resistant to anticancer drugs that inhibit topoisomerase II. <i>Journal of Cellular Physiology</i> , 1993, 155, 414-425.	2.0	18
340	Single-chain immunotoxin fusions between anti-tac and Pseudomonas exotoxin: Relative importance of the two toxin disulfide bonds. <i>Bioconjugate Chemistry</i> , 1993, 4, 112-120.	1.8	69
341	Pseudomonas Exotoxin Conjugated to Monoclonal Antibody MRK16 Specifically Kills Multidrug Resistant Cells in Cultured Renal Carcinomas and In Mdr-Transgenic Mice. <i>Journal of Urology</i> , 1993, 149, 174-178.	0.2	34
342	Recombinant Toxins as Novel Therapeutic Agents. <i>Annual Review of Biochemistry</i> , 1992, 61, 331-354.	5.0	328

#	ARTICLE	IF	CITATIONS
343	<i>Pseudomonas</i> exotoxin: recombinant conjugates as therapeutic agents. <i>Biochemical Society Transactions</i> , 1992, 20, 731-734.	1.6	6
344	Monoclonal Antibody K1 Reacts With Epithelial Mesothelioma but not With Lung Adenocarcinoma. <i>American Journal of Surgical Pathology</i> , 1992, 16, 259-268.	2.1	144
345	Renaturation of a Single-Chain Immunotoxin Facilitated by Chaperones and Protein Disulfide Isomerase. <i>Nature Biotechnology</i> , 1992, 10, 682-685.	9.4	65
346	ATP and GTP as alternative energy sources for vinblastine transport by P-170 in KB-V1 plasma membrane vesicles. <i>FEBS Letters</i> , 1992, 304, 256-260.	1.3	33
347	Reduced mRNA levels for the multidrug-resistance genes in cAMP-dependent protein kinase mutant cell lines. <i>Journal of Cellular Physiology</i> , 1992, 152, 87-94.	2.0	30
348	Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. <i>International Journal of Cancer</i> , 1992, 50, 373-381.	2.3	227
349	Frequent expression of the tumor antigen <i>cak1</i> in squamous-cell carcinomas. <i>International Journal of Cancer</i> , 1992, 51, 548-554.	2.3	55
350	Cytotoxic activity of chimeric proteins composed of acidic fibroblast growth factor and <i>Pseudomonas</i> exotoxin on a variety of cell types. <i>FASEB Journal</i> , 1991, 5, 2843-2849.	0.2	32
351	Clinical evaluation of intraperitoneal <i>Pseudomonas</i> exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer. <i>Journal of Clinical Oncology</i> , 1991, 9, 2095-2103.	0.8	128
352	Molecular manipulations of the multidrug transporter: a new role for transgenic mice ¹ . <i>FASEB Journal</i> , 1991, 5, 2523-2528.	0.2	53
353	New Potent Verapamil Derivatives that Reverse Multidrug Resistance in Human Renal Carcinoma Cells and in Transgenic Mice Expressing the Human MDR 1 Gene. <i>Journal of Urology</i> , 1991, 146, 447-453.	0.2	41
354	Multidrug resistant transgenic mice as a novel pharmacologic tool. <i>BioEssays</i> , 1991, 13, 381-387.	1.2	29
355	Reversal of Drug Resistance in a Human Colon Cancer Xenograft Expressing MDR1 Complementary DNA by In Vivo Administration of MRK-16 Monoclonal Antibody. <i>Journal of the National Cancer Institute</i> , 1991, 83, 1386-1391.	3.0	75
356	Recombinant toxins for cancer treatment. <i>Science</i> , 1991, 254, 1173-1177.	6.0	298
357	In situ Localization of the Human Multidrug-resistance Gene mRNA Using Thymine-Thymine Dimerized Single-stranded cDNA. <i>Japanese Journal of Cancer Research</i> , 1990, 81, 949-955.	1.7	11
358	Genetic basis of multidrug resistance of tumor cells. <i>Journal of Bioenergetics and Biomembranes</i> , 1990, 22, 593-618.	1.0	129
359	Retroviral transfer of a chimeric multidrug resistance-adenosine deaminase gene. <i>FASEB Journal</i> , 1990, 4, 1501-1507.	0.2	39
360	Cytotoxic activities of a fusion protein comprised of TGF β and <i>Pseudomonas</i> exotoxin. <i>FASEB Journal</i> , 1989, 3, 2647-2652.	0.2	78

#	ARTICLE	IF	CITATIONS
361	Retroviruses expressing different levels of the normal epidermal growth factor receptor: Biological properties and new bioassay. <i>Journal of Cellular Biochemistry</i> , 1989, 39, 153-166.	1.2	60
362	An epidermal growth factor-ricin a chain (EGF-RTA)-resistant mutant and an epidermal growth factor-Pseudomonas endotoxin (EGF-PE)-resistant mutant have distinct phenotypes. <i>Journal of Cellular Physiology</i> , 1989, 139, 51-57.	2.0	12
363	Detection of Multidrug Resistance (MDR1) Gene RNA Expression in Human Tumors by a Sensitive Ribonuclease Protection Assay. <i>Japanese Journal of Cancer Research</i> , 1989, 80, 1127-1132.	1.7	26
364	A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. <i>Nature</i> , 1989, 339, 394-397.	13.7	435
365	Epidermal growth factor-dependent growth of human KB cells in a defined medium and altered growth factor requirements of KB mutants resistant to EGF-Pseudomonas exotoxin conjugates. <i>Journal of Cellular Physiology</i> , 1988, 135, 502-508.	2.0	8
366	Genetic characterization of human KB cell lines resistant to epidermal growth factor:Pseudomonas exotoxin conjugates. <i>Journal of Cellular Physiology</i> , 1988, 135, 527-532.	2.0	10
367	Purification and Partial Characterization of an Interleukin 2-Pseudomonas Exotoxin Fusion Protein. <i>Nature Biotechnology</i> , 1988, 6, 1326-1329.	9.4	14
368	Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein. <i>Nature</i> , 1988, 335, 369-372.	13.7	266
369	Functional domains of pseudomonas exotoxin identified by deletion analysis of the gene expressed in <i>E. coli</i> . <i>Cell</i> , 1987, 48, 129-136.	13.5	460
370	ATP-binding properties of P glycoprotein from multidrug-resistant KB cells. <i>FASEB Journal</i> , 1987, 1, 51-54.	0.2	209
371	Mutant KB cells with decreased EGF receptor expression: Biochemical characterization. <i>Journal of Cellular Physiology</i> , 1987, 133, 127-134.	2.0	10
372	Reduction of EGF receptor synthesis by antisense RNA vectors. <i>FEBS Letters</i> , 1986, 206, 319-322.	1.3	9
373	Isolation and genetic characterization of human KB cell lines resistant to multiple drugs. <i>Somatic Cell and Molecular Genetics</i> , 1985, 11, 117-126.	0.7	446
374	Translocation chromosome 7 of A431 cells contains amplification and rearrangement of EGF receptor gene responsible for production of variant mRNA. <i>Somatic Cell and Molecular Genetics</i> , 1985, 11, 477-484.	0.7	27
375	EGF induces receptor down-regulation with no receptor recycling in KB cells. <i>Journal of Cellular Physiology</i> , 1985, 122, 166-170.	2.0	18
376	Characterization of the 3,3',5-Triiodo-L-Thyronine Binding Site on Plasma Membranes from Human Placenta. <i>Endocrinology</i> , 1985, 116, 2621-2630.	1.4	30
377	The Cellular Entry of EGF and Transferrin: A Problem in Intracellular Sorting. <i>Current Topics in Cellular Regulation</i> , 1985, 26, 17-25.	9.6	6
378	Human epidermal growth factor receptor cDNA is homologous to a variety of RNAs overproduced in A431 carcinoma cells. <i>Nature</i> , 1984, 309, 806-810.	13.7	294

#	ARTICLE	IF	CITATIONS
379	Phosphorylation of the solubilized insulin receptor by the gene product of the Rous sarcoma virus, pp60src. <i>Journal of Cellular Biochemistry</i> , 1984, 26, 169-179.	1.2	8
380	Verapamil enhances the toxicity of conjugates of epidermal growth factor with <i>Pseudomonas</i> exotoxin and antitransferrin receptor with <i>pseudomonas</i> exotoxin. <i>Journal of Cellular Physiology</i> , 1984, 120, 271-279.	2.0	52
381	Rous sarcoma virus transformed cells are resistant to cyclic AMP. <i>Journal of Cellular Physiology</i> , 1982, 111, 42-48.	2.0	10
382	Inhibition by bacitracin of high affinity binding of $125 \text{ I-} \hat{1} \pm 2 \text{ M}$ to plasma membranes. <i>FEBS Letters</i> , 1981, 126, 265-268.	1.3	18
383	Sequence rearrangement and duplication of double stranded fibronectin cDNA probably occurring during cDNA synthesis by AMV reverse transcriptase and <i>Escherichia coli</i> DNA polymerase I. <i>Nucleic Acids Research</i> , 1980, 8, 3055-3064.	6.5	44
384	A calcium requirement for movement of cultured cells. <i>Journal of Cellular Physiology</i> , 1979, 101, 101-108.	2.0	25
385	Effect of cell density on energy-dependent calcium uptake by Balb/c 3T3 membranes is independent of protein synthesis and attachment to substratum. <i>Journal of Cellular Physiology</i> , 1979, 101, 109-116.	2.0	6
386	Amines inhibit the clustering of $\hat{1} \pm 2$ -macroglobulin and EGF on the fibroblast cell surface. <i>Nature</i> , 1979, 277, 661-663.	13.7	250
387	Effect of epidermal growth factor on prostaglandin E1 -stimulated accumulation of cyclic AMP in fibroblastic cells. <i>FEBS Letters</i> , 1979, 102, 329-332.	1.3	18
388	Fluorescent rhodamine-labeled thyroid hormone derivatives. <i>FEBS Letters</i> , 1979, 100, 113-116.	1.3	12
389	Decreased binding of epidermal growth factor to BALB/c 3T3 mutant cells defective in glycoprotein synthesis. <i>Nature</i> , 1978, 272, 68-70.	13.7	75
390	Adenylate cyclase in a fibroblast mutant defective in glycolipid and glycoprotein synthesis. <i>Nature</i> , 1978, 275, 223-224.	13.7	4
391	The visualization of fluorescent proteins in living cells by video intensification microscopy (VIM). <i>Cell</i> , 1978, 13, 501-507.	13.5	168
392	Regulation of intracellular calcium in chick embryo fibroblast: Calcium uptake by the microsomal fraction. <i>Journal of Cellular Physiology</i> , 1977, 91, 289-296.	2.0	34
393	Diminished content of plasma membrane-associated myosin in transformed fibroblasts. <i>Nature</i> , 1976, 261, 414-415.	13.7	25
394	Effect of Rho on Transcription of Bacterial Operons. <i>Nature: New Biology</i> , 1973, 241, 260-264.	4.5	150
395	Cyclic AMP and Growth of Fibroblasts: Effect of Environmental pH. <i>Nature: New Biology</i> , 1973, 242, 78-80.	4.5	43
396	Cyclic AMP increases the Adhesion of Fibroblasts to Substratum. <i>Nature: New Biology</i> , 1972, 236, 247-249.	4.5	74

#	ARTICLE	IF	CITATIONS
397	N ⁶ ,O ² -Dibutyryl Adenosine 3',5'-Monophosphate induces Pigment Production in Melanoma Cells. Nature: New Biology, 1972, 237, 267-268.	4.5	109
398	Regulation of Cell Motility by Cyclic AMP. Nature, 1972, 235, 54-56.	13.7	170
399	Lac DNA, RNA Polymerase and Cyclic AMP Receptor Protein, Cyclic AMP, Lac Repressor and Inducer are the Essential Elements for Controlled Lac Transcription. Nature: New Biology, 1971, 231, 139-142.	4.5	244
400	On the Mechanism of Action of lac Repressor. Nature: New Biology, 1971, 233, 67-70.	4.5	38
401	CYCLIC AMP-TREATED SARCOMA CELLS ACQUIRE SEVERAL MORPHOLOGICAL CHARACTERISTICS OF NORMAL FIBROBLASTS. Annals of the New York Academy of Sciences, 1971, 185, 413-416.	1.8	19
402	Role of Cyclic Adenosine 3',5'-Monophosphate and the Cyclic Adenosine 3',5'-Monophosphate Receptor Protein in the Initiation of lac Transcription. Journal of Biological Chemistry, 1971, 246, 7343-7348.	1.6	49
403	Effects of Calcium on ACTH Stimulation of the Adrenal: Separation of Hormone Binding from Adenyl Cyclase Activation. Nature, 1970, 228, 864-866.	13.7	166
404	Regulation of Lac Transcription in Escherichia coli by Cyclic Adenosine 3',5'-Monophosphate. Journal of Biological Chemistry, 1970, 245, 6366-6372.	1.6	22
405	Clinical Applications of Gene Therapy in Cancer: Modification of Sensitivity to Therapeutic Agents. , 0, , 429-453.		0